French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

In July 2025, Sanofi announced that its SAR446597 therapy received fast track designation from the US FDA for treating geographic atrophy due to age-related macular degeneration, highlighting its ...

Sanofi said the talks to sell 50% plus one share of what’s called Opella fits with the company’s broader strategy to focus on innovative medicines and vaccines. About the Author Steve Goldstein ...

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has achieved a milestone associated with its Phase 2/3 ...

Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

They explore Sanofi’s ambition to become a premier immunology powerhouse, how the company is applying venture-style rigor to pipeline decisions, and why cultural transformation -- not quarterly ...

Sanofi's <SASY.PA> most senior strategy boss is set to leave by the end of the month, according to a memo seen by Reuters, in the first major management change under new chief executive Paul ...

Sanofi-aventis CEO Viebacher details strategy post-Genzyme buyout. expand. Chris Viehbacher, CEO, Sanofi-aventis. By Julie M. Donnelly, Boston Business Journal. Apr 12, ...